BG
Bellevue Group Portfolio holdings
AUM
$4.54B
This Quarter Return
+4.36%
1 Year Return
+22.5%
3 Year Return
+98.22%
5 Year Return
+159.37%
10 Year Return
–
AUM
$7.24B
AUM Growth
+$7.24B
(+2.4%)
Cap. Flow
+$197M
Cap. Flow
% of AUM
2.72%
Top 10 Holdings %
Top 10 Hldgs %
34.84%
Holding
226
New
18
Increased
74
Reduced
41
Closed
9
Top Buys
| 1 |
Relay Therapeutics
RLAY
|
$55.4M |
| 2 |
Exact Sciences
EXAS
|
$31M |
| 3 |
Ionis Pharmaceuticals
IONS
|
$22.1M |
| 4 |
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
|
$20.8M |
| 5 |
MTEM
Molecular Templates, Inc.
MTEM
|
$16.9M |
Top Sells
| 1 |
Pacific Biosciences
PACB
|
$44M |
| 2 |
Halozyme
HALO
|
$33.2M |
| 3 |
Evolent Health
EVH
|
$21.8M |
| 4 |
AKCA
Akcea Therapeutics, Inc. Common Stock
AKCA
|
$20.4M |
| 5 |
Medtronic
MDT
|
$15.2M |
Sector Composition
| 1 | Healthcare | 95.98% |
| 2 | Industrials | 0.6% |
| 3 | Technology | 0.53% |
| 4 | Communication Services | 0.41% |
| 5 | Financials | 0.13% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Ionis Pharmaceuticals
IONS
$6.79B
| $414M | 5.71% |
8,716,270
+466,397
| +6% | +$22.1M |
|
2
Neurocrine Biosciences
NBIX
$13.8B
| $317M | 4.38% |
3,297,451
+86,551
| +3% | +$8.32M |
|
3
Incyte
INCY
$16.5B
| $294M | 4.07% |
3,279,450
-13,150
| -0.4% | -$1.18M |
|
4
Vertex Pharmaceuticals
VRTX
$100B
| $261M | 3.61% |
960,600
-22,000
| -2% | -$5.99M |
|
5
argenx
ARGX
$43.6B
| $252M | 3.48% |
959,016
+5,000
| +0.5% | +$1.31M |
|
6
Moderna
MRNA
$9.37B
| $236M | 3.27% |
3,341,950
-3,000
| -0.1% | -$212K |
|
7
Alnylam Pharmaceuticals
ALNY
$58.5B
| $227M | 3.14% |
1,559,805
-50,260
| -3% | -$7.32M |
|
8
Esperion Therapeutics
ESPR
$448M
| $203M | 2.81% |
5,465,715
+162,580
| +3% | +$6.04M |
|
|
ALXN
9
DELISTED
Alexion Pharmaceuticals Inc
ALXN
| $163M | 2.25% |
1,421,128
+8,300
| +0.6% | +$950K |
|
|
MYOK
10
DELISTED
MyoKardia, Inc. Common Stock
MYOK
| $154M | 2.13% |
1,128,400
-79,913
| -7% | -$10.9M |
|
11
Agios Pharmaceuticals
AGIO
$2.19B
| $145M | 2.01% |
4,151,002
+127,429
| +3% | +$4.46M |
|
|
12
Halozyme
HALO
$8.56B
| $144M | 1.99% |
5,469,131
-1,261,421
| -19% | -$33.2M |
|
13
Abbott
ABT
$231B
| $140M | 1.94% |
1,288,285
+4,013
| +0.3% | +$437K |
|
14
MacroGenics
MGNX
$112M
| $133M | 1.84% |
5,282,188
+280,072
| +6% | +$7.06M |
|
15
Intuitive Surgical
ISRG
$170B
| $109M | 1.5% |
153,184
-3,049
| -2% | -$2.16M |
|
16
UnitedHealth
UNH
$281B
| $101M | 1.4% |
324,053
+17,417
| +6% | +$5.43M |
|
17
Humana
HUM
$36.5B
| $101M | 1.4% |
243,996
+8,356
| +4% | +$3.46M |
|
18
Bristol-Myers Squibb
BMY
$96B
| $99.2M | 1.37% |
1,645,912
+33,800
| +2% | +$2.04M |
|
19
Danaher
DHR
$147B
| $97.6M | 1.35% |
453,384
+1,751
| +0.4% | +$377K |
|
|
SAGE
20
DELISTED
Sage Therapeutics
SAGE
| $96.5M | 1.33% |
1,579,504
+164,000
| +12% | +$10M |
|
21
Elevance Health
ELV
$71.8B
| $93.8M | 1.3% |
349,123
+39,098
| +13% | +$10.5M |
|
|
ITCI
22
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $91.9M | 1.27% |
3,579,919
-200,000
| -5% | -$5.13M |
|
23
Fate Therapeutics
FATE
$120M
| $88.6M | 1.22% |
2,217,500
+256,100
| +13% | +$10.2M |
|
|
24
Medtronic
MDT
$119B
| $86.4M | 1.19% |
831,450
-146,073
| -15% | -$15.2M |
|
|
RDUS
25
DELISTED
Radius Health, Inc.
RDUS
| $84.3M | 1.16% |
7,431,414
+424,029
| +6% | +$4.81M |
|